An investigation for investors in NASDAQ:MCRB shares over potential securities laws violations by Seres Therapeutics and certain of its directors and officers in connection certain financial statements was announced.
Investors who purchased shares of Seres Therapeutics Inc (NASDAQ:MCRB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Seres Therapeutics Inc (NASDAQ:MCRB) concerning whether a series of statements by Seres Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On July 29, 2016, Seres Therapeutics Inc disclosed that its Phase 2 clinical study for ECOSPOR™ did not meet its primary endpoint of reducing the relative risk of Clostridium difficle infection recurrence. Shares of Seres Therapeutics Inc (NASDAQ:MCRB) declined on July 29, 2016 to as low as $8.05 per share.
According to the investigation just a couple days prior to this announcement, the Company’s President, CEO and Chairman of the Board sold 20,000 shares of Seres at $35 per share, and another Company insider sold 38,064 shares at $35.12 per share.
On September 1, 2016, NASDAQ:MCRB closed at $10.15 per share
Those who purchased NASDAQ:MCRB shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com